Collectively, these studies highlight a critical role for the activated RhoA signaling in AT2 cells in allergic airway inflammation and provide a potential therapeutic effect of anti–RhoA-SLC26A4 approaches in patients with asthma. Here, SLC26A4 is linked to asthma.